Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 38 - Medicinal preparations containing peptides
Patents for A61K 38 - Medicinal preparations containing peptides (316,240)
11/2003
11/27/2003US20030219430 Methods of preventing or treating brain ischemia or brain injury
11/27/2003US20030219428 Deoxyribonuclease formed by genetic engineering, used for prophylaxis respiratory system disorders, lupus erythematosus and/or genetic disorders
11/27/2003US20030219427 Modulation of nuclear factor kappa beta activity using tumor progression locus (TPL-2) molecules; phosphorylation of proteins; controlling immune and inflammatory responses
11/27/2003US20030219426 Endostatins used as antiproliferative agents or angiogenesis inhibitors for prophylaxis of tumors, or as contraceptives
11/27/2003US20030219425 Modulation of graft versus host disease by providing the organs with gene regulatory peptides, which control translocation and/or transcription factors; immunology
11/27/2003US20030219424 Polynucleotide codes for amino acid sequences used for medical diagnosis, prophylaxis autoimmune diseases, as antiallergens or antitumor agents
11/27/2003US20030219423 Methods of inducing or enhancing connective tissue repair
11/27/2003US20030219419 Alteration of cell membrane for new functions
11/27/2003US20030219415 Methods for delivering DNA to muscle cells using recombinant adeno-associated virus virions
11/27/2003US20030219413 Method for overexpression of zwitterionic polysaccharides
11/27/2003US20030219411 Modulators of the function of FAS receptors and other proteins
11/27/2003US20030219410 Adenoviral vectors for modulating the cellular activities associated to PODs
11/27/2003US20030219409 Eukaryotic gene expression cassette and uses thereof
11/27/2003US20030219406 Beta-2-glycoprotein is an inhibitor of angiogenesis
11/27/2003US20030219405 Oral administration of interferon-tau
11/27/2003US20030219404 A therapeutic polypeptide drug conjugated with two chains of polyoxyethylene glycol, linked to a cyclohexane ring; high molecular weight, stability, nontoxic, sustained release
11/27/2003US20030219402 Drug delivery of a fusion protein comprising plurality of component molecules linked with a linker, containing an enzyme cleavage site to be cleaved by an enzyme in a treated subject
11/27/2003US20030219400 Methods for treating or inhibiting neurotoxin-mediated syndromes
11/27/2003US20030219387 Local delivery of agents for disruption and inhibition of bacterial biofilm for treatment of periodontal disease
11/27/2003US20030219386 Antiscarring agent
11/27/2003US20030219382 Cancer-linked gene as target for chemotherapy
11/27/2003US20030219379 Antiproliferative agent
11/27/2003US20030219378 Membrane-permeant peptide complexes for medical imaging, diagnostics, and pharmaceutical therapy
11/27/2003US20030219376 Progression elevated Gene-3 and uses thereof
11/27/2003US20030219375 Membrane-permeant peptide complexes for medical imaging, diagnostics, and pharmaceutical therapy
11/27/2003CA2830619A1 Glucan-based vaccines
11/27/2003CA2493825A1 Means for use in treating diseases correlated with or caused by non-physiological levels of microtubule-associated pp2ac
11/27/2003CA2487642A1 Collagen and method for producing same
11/27/2003CA2487247A1 Drug therapy for celiac sprue
11/27/2003CA2486583A1 Marker molecules associated with lung tumors
11/27/2003CA2486576A1 Sodium channel regulators and modulators
11/27/2003CA2486483A1 Preparation and standardization of immunomodulatory peptide-linked glucans with verifiable oral absorbability from coriolus versicolor
11/27/2003CA2486342A1 Compounds which can block the response to chemical substances or thermal stimuli or mediators of inflammation of nociceptors, production method thereof and compositions containingsame
11/27/2003CA2486313A1 Composition for treating or preventing hyperuricemia
11/27/2003CA2486302A1 Methods for the prevention and/or the treatment of neurological disorders
11/27/2003CA2486141A1 Methods and compositions using selective cytokine inhibitory drugs for treatment and management of cancers and other diseases
11/27/2003CA2486127A1 Method of treating dyslipidemic disorders
11/27/2003CA2486112A1 Allergen mutants
11/27/2003CA2486060A1 Cancer-linked gene as target for chemotherapy
11/27/2003CA2485989A1 Methods and compositions for the treatment of ischemic reperfusion
11/27/2003CA2485981A1 Cancer-linked gene as target for chemotherapy
11/27/2003CA2485969A1 Carotene synthase gene and uses therefor
11/27/2003CA2485847A1 Glucan-based vaccines
11/27/2003CA2485463A1 A direct cellular energy delivery system
11/27/2003CA2485399A1 Co-grinding process for the preparation of a ternary composition
11/27/2003CA2484719A1 Scytovirins and related conjugates, fusion proteins, nucleic acids, vectors, host cells, compositions, antibodies and methods of using scytovirins
11/27/2003CA2484512A1 Treatment of cataracts and other ophthalmic diseases
11/27/2003CA2482458A1 Controllably degradable polymeric biomolecule or drug carrier and method of synthesizing said carrier
11/27/2003CA2471879A1 Pharmaceutical composition containing ghrelin
11/27/2003CA2390972A1 Bovine viral diarrhea virus (bvdv) p80 and p80.delta.50 proteins as inducers of cell apoptosis
11/27/2003CA2383607A1 Bovine viral diarrhea virus (bvdv) p80 and p80.delta.50 proteins as inducers of cell apoptosis in vitro
11/26/2003EP1365247A1 Diagnostics and therapeutics for diseases associated with arginine vasopressin receptor 3 (AVPR3)
11/26/2003EP1365246A1 Diagnostics and therapeutics for diseases associated with neuromedin U2 receptor (NMU2)
11/26/2003EP1365245A1 Diagnostics and therapeutics for diseases associated with chemokine receptor 11 (CCR11)
11/26/2003EP1365244A1 Diagnostics and therapeutics for diseases associated with arginine vasopressin receptor 2 (AVPR2)
11/26/2003EP1365032A1 Marker molecules associated with lung tumors
11/26/2003EP1365028A1 Method for expression of PDGF or IGF proteins in yeast
11/26/2003EP1365024A1 Traf3-binding b cell-specific receptor
11/26/2003EP1365018A1 CD100 semaphorin in myelination
11/26/2003EP1364969A2 Human tissue factor related DNA segments, polypeptides and antibodies
11/26/2003EP1364967A2 Glucagon-like insulinotropic peptides, compositions and methods
11/26/2003EP1364963A1 A novel natural antibacterial peptide, the nucleotide sequence encoding it and the use thereof
11/26/2003EP1364962A1 Use of monocarboxylate transporter proteins for thyroid hormone transport
11/26/2003EP1364960A1 Peptide derivatives
11/26/2003EP1364658A1 Use of varying ratios of gonadotrophins in controlled ovarian hyperstimulation
11/26/2003EP1364657A1 Remedies for tumor in hematopoietic organs
11/26/2003EP1364656A2 Use of bone morphogenetic proteins for healing and repair of connective tissue attachment
11/26/2003EP1364655A1 Method for enhancing functional recovery of motor coordination, speech or sensory perception after central nervous system ischemia or trauma
11/26/2003EP1364654A1 Eye drops
11/26/2003EP1364653A1 Casoase 3 inhibitors
11/26/2003EP1364647A1 Hypoglycemic agent
11/26/2003EP1364645A1 Pharmaceutical combinations for topical use based on iron chelators, metalloprotease inhibitors and factor XIII for the treatment of lipodermatosclerosis and trophic lesions of the cutaneous tissues and muccous membranes
11/26/2003EP1364067A2 Prc17: an amplified cancer gene
11/26/2003EP1364038A2 Adenovirus particles with mutagenized fiber proteins
11/26/2003EP1364029A1 Fusion protein for the secretion of a protein of interest into the supernatant of the bacterial culture
11/26/2003EP1364027A2 Zinc finger binding domains for nucleotide sequence ann
11/26/2003EP1364026A2 Human g protein-coupled receptor
11/26/2003EP1364023A2 Method of diagnosing and treating cartilage disorders
11/26/2003EP1364022A2 Human leucine-rich repeat containing protein, hlrrbm1, expressed predominately in bone marrow
11/26/2003EP1364021A2 Compositions and methods relating to colon specific genes and proteins
11/26/2003EP1364019A2 Methods and compositions relating to muscle specific sarcomeric calcineurin-binding proteins (calsarcins)
11/26/2003EP1364018A2 Isolated human nuclear hormone receptors, nucleic acid molecules encoding human nuclear hormone receptors, and uses thereof
11/26/2003EP1364017A2 Inflammation related g-protein coupled receptor
11/26/2003EP1364016A2 Secreted proteins and their uses
11/26/2003EP1364015A2 Molecules for diagnostics and therapeutics
11/26/2003EP1364014A2 Novx proteins and nucleic acids encoding same. diagnostic and therapeutic uses
11/26/2003EP1364011A2 Modified thrombopoietin with reduced immunogenicity
11/26/2003EP1364009A2 Regulatable, catalytically active nucleic acids
11/26/2003EP1364008A2 Methods for enhancing targeted gene alteration using oligonucleotides
11/26/2003EP1364004A2 Administration of nucleic acid sequence to female animal
11/26/2003EP1364002A2 Process for the preparation of neutrophil inhibitory factor
11/26/2003EP1363993A2 METHODS OF TREATING INFLAMMATORY AND IMMUNE DISEASES USING INHIBITORS OF I$g(k)B KINASE (IKK)
11/26/2003EP1363948A1 Polypeptide of a p53 protein-specific murine alpha/beta t-cell receptor, nucleic acids coding therefor and use thereof
11/26/2003EP1363945A2 Modified derivatives of cck-8
11/26/2003EP1363944A2 High-affinity antagonists of elr-cxc chemokines
11/26/2003EP1363943A2 Interferon regulatory factor-1/human estrogen receptor fusion protein and its use for treating carcinomas
11/26/2003EP1363942A2 Polypeptide from a hdm2 protein specific murine alpha/beta t-cell receptors, nucleic acids coding for the above and use thereof
11/26/2003EP1363940A1 Tumour peptide antigen produced from human mdm2 proto-oncogene
11/26/2003EP1363939A2 Peptides for use in the treatment of alzheimer's disease
11/26/2003EP1363938A2 Molecular vaccine linking an endoplasmic reticulum chaperone polypeptide to an antigen
1 ... 1725 1726 1727 1728 1729 1730 1731 1732 1733 1734 1735 1736 1737 1738 1739 1740 1741 1742 1743 1744 1745 ... 3163